Free Newsletter
FDA to review GSK's rotavirus vaccine
Free newsletter via e-mail
Tools
The feds have agreed to consider allowing GlaxoSmithKline to sell its rotavirus vaccine, Rotarix, in the U.S. Already licensed in nearly 100 countries, Rotarix is designed to protect children from the virus, which can cause severe diarrhea and dehydration. It would compete against RotaTeq, Merck's product, which is already approved for sale. Several medical societies and the U.S. government recommend that all infants receive rotavirus vaccinations.
- see this release
- here's the report from the Triangle Business Journal
- and here's the AP report
More stories about GlaxoSmithKline
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
